Clinical Trial Search

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.9; 96.2; 74.1; 100.0 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 100 percentage of participants

Primary: Sustained Virologic Response (SVR) — 62 percentage of participants

Primary: Virological Response (Intention to Treat) — 19; 21; 7; 2 participants

Primary: Sustained Virologic Response — 87; 117 participants — p=< 0.001

Primary: Change From Baseline (BL) to Week 72 (WK72) in 36-Item Short-Form Health Survey (SF-36) Scores — 87.27; 87.33; -1.56; 81.71 score on a scale

Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects

Primary: Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase…

Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants

Primary: Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation — 10 Participants

Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale

Primary: Sustained Virologic Response (SVR)Rate — 130; 72 participants — p=< 0.001

Primary: Number of Participants Not Eligible for Antiviral Treatment by Reason for Non-eligibility — 144; 77; 17; 7 participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 97.1; 96.3; 100; 100 percentage of participants

Primary: Mean Log Change in Viral Load From Baseline (Day 1) to Day 28 — 0.30; 0.00; 0.18; 0.04 copies/mL on log scale

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 83.3; 94.3; 87.8 percentage of participants…

Primary: Number of Participants With Sustained Virological Response at Week 12 (SVR12) — 2; 2 participants

Primary: Number of Participants With Sustained Virologic Response — 70 Participants

Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants

Primary: Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy. — 3 participants

Primary: Number of Participants With Severe Adverse Reactions and/or With Abnormal Clinical Laboratory Values That Are Related to Treatment — 0 Participants

Primary: Change in Serum HCV RNA Viral Titer From Baseline to 28 Days — -0.46; -0.11 log IU/ml

Primary: The Percentage of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 90; 80 Percentage of subjects

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment — 96.4 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN…

Primary: Average Change in Urine Tumor Necrosis Factor (TNF)-Alpha From Baseline to Post-treatment — -0.05 ng/g

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.0; 0 percentage of participants — p=< 0.001

Primary: Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS) — 0; 0 Metavir units per one year (52 weeks) — p=0.58

Primary: Sustained Virological Response (SVR): Percentage of Participants Who Were HCV Seronegative at 6 Months After Completing Therapy — 59.5; 58.3 percentage of participants

Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in the Intention-to-Treat (ITT) Population — 96.2 percentage of…